COVID-19 Diagnostics Market Rising in United States | Fortune Business Insights
The global COVID-19 diagnostics market size was USD 16.05 billion in 2020. The market is projected to drop from USD 20.05 billion in 2021 to USD 9.20 billion in 2028 at a CAGR of -10.5% in the 2021-2028 period. This information is published by Fortune Business Insights™ in its report titled, “COVID-19 Diagnostics Market, 2021-2028.”
According to our expert analysts, the coronavirus outbreak was stated as a public
health emergency in January 2020 by the World Health Organization (WHO). Since
then, the amount of COVID-19 positive cases in several nations has elevated
drastically. As per statistical data presented by Worldometer, in May 2021, the
U.S. registered the maximum COVID-19 cases across the globe, staying
responsible for approximately 96.2% in the North American region.
The abrupt
advent of the crisis has noted augmented COVID-19 diagnostic happenings,
treatment processes, and an upsurge in R&D events for the development of
diagnostics, such as molecular assessments and point-of-care tests, among
others.
Get
Sample PDF Brochure: https://www.fortunebusinessinsights.com/enquiry/sample/covid-19-diagnostics-market-103291
North America |
United States, Canada and Mexico |
Europe |
Germany, UK, France, Italy, Russia and Turkey
etc. |
Asia-Pacific |
China, Japan, Korea, India, Australia, Indonesia,
Thailand, Philippines, Malaysia and Vietnam etc. |
South America |
Brazil, Argentina, Columbia etc. |
Middle East & Africa |
Saudi Arabia, UAE, Egypt, Nigeria and South
Africa |
Demand for COVID-19 Diagnostics Experienced Healthy Growth during the Pandemic
Diagnostic technologies, such as Point of Care tests and molecular tests, experienced robust demand amid the COVID-19 pandemic, with many countries witnessing an exponential surge in coronavirus cases. Companies offering diagnostic solutions witnessed tremendous opportunities during the pandemic. Major companies, such as Abbott, Bio-Rad, Roche, and Thermo Fisher Scientific, increased their R&D capacity to develop novel technologies to fight against the pandemic. However, strict restrictions due to COVID-19 caused slight disturbance in the supply chains of this market.
Industry
Development
March
2021: Roche Diagnostics declared the permission for Emergency Use
Authorization (EUA), received from the U.S. Food and Drug Administration (FDA)
meant for COVID-19 rapid antigen test that is intended for usage by healthcare
experts in point-of-care situations with patients suffering through symptoms of
COVID-19.
Speak
To Our Analyst: https://www.fortunebusinessinsights.com/enquiry/speak-to-analyst/covid-19-diagnostics-market-103291
About Us:
Fortune Business Insights™ delivers accurate data and innovative
corporate analysis, helping organizations of all sizes make appropriate
decisions. We tailor novel solutions for our clients, assisting them to address
various challenges distinct to their businesses. Our aim is to empower them with
holistic market intelligence, providing a granular overview of the market they
are operating in.
Contact Us:
Fortune Business Insights™ Pvt. Ltd.
US :+1 424 253 0390
UK : +44 2071 939123
APAC : +91 744 740 1245
Email: sales@fortunebusinessinsights.com
Comments
Post a Comment